These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

610 related items for PubMed ID: 19731767

  • 1. Immune response to measles vaccine after mass vaccination in Urmia, Islamic Republic of Iran.
    Yekta Z, Pourali R, Taravati MR, Shahabi S, Salary S, Khalily F, Farzin A.
    East Mediterr Health J; 2009; 15(3):516-25. PubMed ID: 19731767
    [Abstract] [Full Text] [Related]

  • 2. Distinguishing between primary measles infection and vaccine failure reinfection by IgG avidity assay.
    Hamkar R, Mahmoodi M, Nategh R, Jelyani KN, Eslami MB, Mohktari-Azad T.
    East Mediterr Health J; 2006 Nov; 12(6):775-82. PubMed ID: 17333822
    [Abstract] [Full Text] [Related]

  • 3. Humoral and cellular immune response after measles vaccination in Taiwan.
    Huang CL, Yang YH, Wang LC, Lin YT, Tsai YY, Chiang BL.
    J Microbiol Immunol Infect; 2005 Jun; 38(3):169-75. PubMed ID: 15986066
    [Abstract] [Full Text] [Related]

  • 4. Prevalence of measles antibody in children of different ages in Shiraz, Islamic Republic of Iran.
    Karimi A, Arjomandi A, Alborzi A, Rasouli M, Kadivar MR, Obood B, Pourabbas B.
    East Mediterr Health J; 2004 Jun; 10(4-5):468-73. PubMed ID: 16335636
    [Abstract] [Full Text] [Related]

  • 5. Measles seroepidemiology among adolescents and young adults: response to revaccination.
    Saffar MJ, Alraza-Amiri M, Ajami A, Baba-Mahmoodi F, Khalilian AR, Vahidshahi C, Shamsizadeh A.
    East Mediterr Health J; 2006 Sep; 12(5):573-81. PubMed ID: 17333796
    [Abstract] [Full Text] [Related]

  • 6. Progress in measles and rubella elimination in Iran.
    Esteghamati A, Gouya MM, Zahraei SM, Dadras MN, Rashidi A, Mahoney F.
    Pediatr Infect Dis J; 2007 Dec; 26(12):1137-41. PubMed ID: 18043452
    [Abstract] [Full Text] [Related]

  • 7. Evaluation of immunity against rubella in Iranian after mass campaign for measles-rubella vaccination on December 2003.
    Hamkar R, Jalilvand S, Mokhtari-Azad T, Jelyani KN, Nategh R.
    Am J Infect Control; 2006 Nov; 34(9):588-92. PubMed ID: 17097454
    [Abstract] [Full Text] [Related]

  • 8. Evaluation of the measles-rubella mass vaccination campaign in the population covered by Tehran University of Medical Sciences.
    Majdzadeh R, Moradi A, Zeraati H, Sepanlou SG, Zamani G, Zonobi V.
    East Mediterr Health J; 2008 Nov; 14(4):810-7. PubMed ID: 19166164
    [Abstract] [Full Text] [Related]

  • 9. Sustained measles elimination in Australia and priorities for long term maintenance.
    Gidding HF, Wood J, MacIntyre CR, Kelly H, Lambert SB, Gilbert GL, McIntyre PB.
    Vaccine; 2007 May 04; 25(18):3574-80. PubMed ID: 17300858
    [Abstract] [Full Text] [Related]

  • 10. Immunogenicity and efficacy of Hoshino strain of mumps vaccine in Iran; two years study.
    Avijgan M, Hafizi M, Moghni M, Kheiri S, Esteghamati A, Sarikhani S.
    East Afr J Public Health; 2011 Jun 04; 8(2):88-91. PubMed ID: 22066292
    [Abstract] [Full Text] [Related]

  • 11. Human leukocyte antigen haplotypes in the genetic control of immune response to measles-mumps-rubella vaccine.
    Ovsyannikova IG, Pankratz VS, Vierkant RA, Jacobson RM, Poland GA.
    J Infect Dis; 2006 Mar 01; 193(5):655-63. PubMed ID: 16453260
    [Abstract] [Full Text] [Related]

  • 12. Predicting and comparing long-term measles antibody profiles of different immunization policies.
    Lee MS, Nokes DJ.
    Bull World Health Organ; 2001 Mar 01; 79(7):615-24. PubMed ID: 11477964
    [Abstract] [Full Text] [Related]

  • 13. Efficacy of measles and rubella vaccination one year after the nationwide campaign in Shiraz, Iran.
    Pourabbas B, Ziyaeyan M, Alborzi A, Mardaneh J.
    Int J Infect Dis; 2008 Jan 01; 12(1):43-6. PubMed ID: 17950020
    [Abstract] [Full Text] [Related]

  • 14. Prevalence of measles antibodies before and after vaccination in previously unvaccinated children of the Cordillera Province (Santa Cruz Department, Bolivia).
    Guglielmetti P, Bianchi Bandinelli ML, Bartoloni A, Gamboa H, Roselli M, Valensin PE.
    J Trop Med Hyg; 1994 Aug 01; 97(4):231-5. PubMed ID: 8064946
    [Abstract] [Full Text] [Related]

  • 15. Successful control and impending elimination of measles in the Islamic Republic of Iran.
    Zahraei SM, Gouya MM, Azad TM, Soltanshahi R, Sabouri A, Naouri B, Alexander JP.
    J Infect Dis; 2011 Jul 01; 204 Suppl 1():S305-11. PubMed ID: 21666178
    [Abstract] [Full Text] [Related]

  • 16. Waning antibodies in measles and rubella vaccinees--a longitudinal study.
    Kremer JR, Schneider F, Muller CP.
    Vaccine; 2006 Mar 24; 24(14):2594-601. PubMed ID: 16427163
    [Abstract] [Full Text] [Related]

  • 17. Serosurvey of measles, mumps and rubella antibodies in Saudi children.
    Al-Mazrou YY, Khalil MK, Tischer A, Al-Jeffri MH, Al-Ghamdi YS, Bakhsh MM, Mishkas AA, Elgizouli SA.
    Saudi Med J; 2005 Oct 24; 26(10):1551-4. PubMed ID: 16228054
    [Abstract] [Full Text] [Related]

  • 18. Assessing seropositivity of MMR antibodies in individuals aged 2-22: evaluating routine vaccination effectiveness after the 2003 mass campaign-a study from Iran's National Measles Laboratory.
    Ghafoori F, Mokhtari-Azad T, Foroushani AR, Farahmand M, Shadab A, Salimi V.
    BMC Infect Dis; 2024 Jul 12; 24(1):696. PubMed ID: 38997625
    [Abstract] [Full Text] [Related]

  • 19. Prevalence of IgG antibody against measles, mumps and rubella in bangladeshi children: a pilot study to evaluate the need for integrated vaccination strategy.
    Sultana R, Rahman MM, Hassan Z, Hassan MS.
    Scand J Immunol; 2006 Dec 12; 64(6):684-9. PubMed ID: 17083626
    [Abstract] [Full Text] [Related]

  • 20. Seroprevalence of mumps before inclusion of mumps vaccination in the Iranian expanded programme on immunization.
    Avijgan M, Habibian R, Kheiri S.
    East Mediterr Health J; 2009 Dec 12; 15(2):295-301. PubMed ID: 19554975
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 31.